Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD).

Mielnik, Pawel; Sexton, Joseph; Fagerli, Karen M; Bakland, Gunnstein; Hu, Yi; Kristianslund, Eirik K; Hoff, Mari; Wierød, Ada; Kvien, Tore K

Mielnik, Pawel; Sexton, Joseph; Fagerli, Karen M; Bakland, Gunnstein; Hu, Yi; Kristianslund, Eirik K; Hoff, Mari; Wierød, Ada; Kvien, Tore K.

Afiliação

Mielnik P; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde, Førde, Norway.
Sexton J; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
Fagerli KM; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
Bakland G; Department of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway.
Hu Y; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway.
Kristianslund EK; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
Hoff M; Department of Rheumatology, St. Olavs Hospital, Trondheim, Norway.
Wierød A; Department of Neuromedicine and Movement Science, NTNU-Norwegian University of Science and Technology, Trondheim, Norway.
Kvien TK; Department of Rheumatology, Vestre Viken/Drammen Hospital, Drammen, Norway.

Rheumatol Adv Pract ; 7(2): rkad053, 2023.

Article em En | MEDLINE | ID: mdl-37431434

Palavras-chave

LEF; MTX; RA; SSZ; adverse events; discontinuation

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Rheumatol Adv Pract Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Noruega País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google